Wolverine Trading
CLDX icon

Wolverine Trading’s Celldex Therapeutics CLDX Stock Holding History

Wolverine Trading’s Portfolio CLDX Stock Details CLDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-14,400
Closed -$571K – 4597
2023
Q4 		$571K Buy
14,400
+2,000
+16% +$58.8K ﹤0.01% 2809
2023
Q3 		$341K Sell
12,400
-1,800
-13% -$56.4K ﹤0.01% 3164
2023
Q2 		$491K Buy
+14,200
New +$479K ﹤0.01% 2621
2023
Q1 		– Sell
-5,300
Closed -$236K – 4307
2022
Q4 		$236K Buy
+5,300
New +$189K ﹤0.01% 2981
2022
Q3 		– Sell
-16,900
Closed -$470K – 4674
2022
Q2 		$470K Buy
16,900
+6,300
+59% +$183K ﹤0.01% 2607
2022
Q1 		$367K Sell
10,600
-1,600
-13% -$51.1K ﹤0.01% 3648
2021
Q4 		$475K Buy
12,200
+5,400
+79% +$235K ﹤0.01% 3523
2021
Q3 		$353K Buy
+6,800
New +$319K ﹤0.01% 4457
2020
Q3 		– Sell
-11,000
Closed -$137K – 4566
2020
Q2 		$137K Buy
+11,000
New +$48.8K ﹤0.01% 4024
2019
Q3 		– Sell
-10,700
Closed -$29K – 4399
2019
Q2 		$29K Buy
+10,700
New +$36.3K ﹤0.01% 4263
2018
Q1 		– Sell
-1,760
Closed -$75K – 5145
2017
Q4 		$75K Sell
1,760
-620
-26% -$26.6K ﹤0.01% 4521
2017
Q3 		$102K Sell
2,380
-640
-21% -$24K ﹤0.01% 4066
2017
Q2 		$113K Sell
3,020
-1,407
-32% -$62.2K ﹤0.01% 3855
2017
Q1 		$239K Buy
4,427
+907
+26% +$47.2K ﹤0.01% 3303
2016
Q4 		$187K Buy
+3,520
New +$200K ﹤0.01% 3802
2016
Q3 		– Sell
-3,787
Closed -$251K – 4632
2016
Q2 		$251K Buy
+3,787
New +$240K ﹤0.01% 3011

Other funds holding CLDX

KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Wolverine Trading's CLDX Position: Q1 2024 in Review

Wolverine Trading sold out of Celldex Therapeutics (CLDX) in Q1 2024, closing a stake of 5,058 shares — an estimated $201K sold.

Wolverine Trading first reported a position in CLDX in Q4 2016 and held it in 8 quarters. The position peaked at $201K in Q4 2023. 197 funds tracked by Wall St. Rank hold CLDX as of Q1 2024.

  • Wolverine Trading reported no remaining Celldex Therapeutics position as of Q1 2024 after selling out during the quarter.
  • Wolverine Trading sold 5,058 Celldex Therapeutics shares in Q1 2024, an estimated $201K.
  • Wolverine Trading first reported a position in Celldex Therapeutics in Q4 2016 and held it in 8 quarters.
  • Wolverine Trading's Celldex Therapeutics position peaked at $201K in Q4 2023.
  • 197 funds tracked by Wall St. Rank held Celldex Therapeutics as of Q1 2024.

Based on Wolverine Trading's 13F filing for Q1 2024, filed 15 May 2024.